Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Back to Search
Print
Bookmark Trial

NCT00472836

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anaheim, California, 92801, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Normal Subjects: 1.Healthy. 2.Matched for age (± 5 yrs), weight (± 10 kg), and gender ratio (± 2 subjects per gender).

- Subjects with Renal Disease: 1. Severe impairment (Creatinine clearance <30 mL/min) 2. Stable renal disease:no change in the last 30 days. 3. Stable dose of medication and/or treatment. 4. Reasonably well-controlled type 1 and type 2 diabetics

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- All subjects: Non-prescribed use of drugs of abuse/ recreational drugs; recent
treatment with experimental drugs or herbal experiments; EKG and blood pressure
parameters falling outside of protocol-specified limits; history of regular alcohol or
tobacco use exceeding protocol-specified limits


- Normal subjects: Medically important health conditions; recent use of prescription or
non-prescription medications.


- Subjects with renal disease: Subjects requiring dialysis; certain chronic medical
conditions; patients who have received renal transplant; severe and/or poorly
controlled diabetes; Treatment with protocol-specified drugs that may alter the way
the body absorbs or processes CP-945,598.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

ObesitySafety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
NCT00331175
  1. New Haven, Connecticut
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityA 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
NCT00391196
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Huntsville, Alabama
  4. Mobile, Alabama
  5. Chandler, Arizona
  6. Mesa, Arizona
  7. Phoenix, Arizona
  8. Fresno, California
  9. Palm Springs, California
  10. Tustin, California
  11. Walnut Creek, California
  12. New Britain, Connecticut
  13. Washington, District of Columbia
  14. Orlando, Florida
  15. West Palm Beach, Florida
  16. Honolulu, Hawaii
  17. Gurnee, Illinois
  18. Madisonville, Kentucky
  19. Baton Rouge, Louisiana
  20. Metairie, Louisiana
  21. Auburn, Maine
  22. Scarborough, Maine
  23. Baltimore, Maryland
  24. Bay City, Michigan
  25. Troy, Michigan
  26. Edina, Minnesota
  27. Jefferson City, Missouri
  28. Albuquerque, New Mexico
  29. Buffalo, New York
  30. New York, New York
  31. Greenville, North Carolina
  32. Beaver, Pennsylvania
  33. Cumberland, Rhode Island
  34. Pawtucket, Rhode Island
  35. Greer, South Carolina
  36. Bristol, Tennessee
  37. Nashville, Tennessee
  38. Dallas, Texas
  39. Dallas, Texas
  40. San Antonio, Texas
  41. San Antonio, Texas
  42. Renton, Washington
  43. Morgantown, West Virginia
  44. Buenos Aires,
  45. Buenos Aires,
  46. Buenos Aires,
  47. Garran, Australian Capital Territory
  48. Wollongong, New South Wales
  49. Adelaide, South Australia
  50. Box Hill, Victoria
  51. Nedlands, Western Australia
  52. Curitiba, PR
  53. Porto Alegre, RS
  54. São Paulo, SP
  55. São Paulo, SP
  56. São Paulo, SP
  57. São Paulo, SP
  58. Red Deer, Alberta
  59. Coquitlam, British Columbia
  60. Winnipeg, Manitoba
  61. Thornhill, Ontario
  62. Charlottetown, Prince Edward Island
  63. L'Ancienne-Lorette, Quebec
  64. Saint-Marc-des-Carrières, Quebec
  65. Breclav,
  66. Ceske Budejovice,
  67. Olomouc,
  68. Praha 2,
  69. Praha 4 - Krc,
  70. Berlin,
  71. Dresden,
  72. Duesseldorf,
  73. Hamburg,
  74. Leipzig,
  75. Mittweida,
  76. Tampico, Cd. Madero
  77. Mexico, DF
  78. Guadalajara, Jalisco
  79. Monterrey, Nuevo León
  80. Banska Bystrica,
  81. Bratislava,
  82. Lubochna,
  83. Nitra,
  84. Goteborg,
  85. Huddinge,
  86. Edinburgh, Lothian
  87. Bath, Somerset
  88. Coventry,
  89. Dumfries,
  90. Dundee,
  91. Luton,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityA Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects
NCT01472848
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ObesityStudy of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
NCT00471172
  1. Los Angeles, California
  2. Clearwater, Florida
  3. Kissimmee, Florida
  4. Pembroke Pines, Florida
  5. Lexington, Kentucky
  6. Louisville, Kentucky
  7. Milford, Massachusetts
  8. Charlotte, North Carolina
  9. Harleysville, Pennsylvania
  10. Warwick, Rhode Island
  11. Nashville, Tennessee
  12. Milwaukee, Wisconsin
ALL GENDERS
25 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
Official Title  ICMJE A Phase 1, Open-Label, Parallel Group, Multiple-Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of CP-945,598 Administered To Subjects With Severely Impaired And Normal Renal Function
Brief Summary CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism. This study will therefore compare the pharmacokinetics (time course of drug concentrations in the body), safety and tolerability of CP-945,598 in patients with severe renal impairment and healthy control subjects.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Obesity
Intervention  ICMJE
  • Drug: CP-945,598
    Administration of CP-945,598 in subjects with normal renal function.
  • Drug: CP-945,598
    Administration of CP-945,598 in subjects with severe renal impairment.
Study Arms  ICMJE
  • Experimental: Normal renal function
    Intervention: Drug: CP-945,598
  • Experimental: Severe renal impairment
    Intervention: Drug: CP-945,598
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 23, 2009)		17
Original Enrollment  ICMJE
 (submitted: May 11, 2007)		16
Actual Study Completion Date  ICMJE October 2008
Actual Primary Completion Date October 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Normal Subjects: 1.Healthy. 2.Matched for age (± 5 yrs), weight (± 10 kg), and gender ratio (± 2 subjects per gender).
  • Subjects with Renal Disease: 1. Severe impairment (Creatinine clearance <30 mL/min) 2. Stable renal disease:no change in the last 30 days. 3. Stable dose of medication and/or treatment. 4. Reasonably well-controlled type 1 and type 2 diabetics

Exclusion Criteria:

  • All subjects: Non-prescribed use of drugs of abuse/ recreational drugs; recent treatment with experimental drugs or herbal experiments; EKG and blood pressure parameters falling outside of protocol-specified limits; history of regular alcohol or tobacco use exceeding protocol-specified limits
  • Normal subjects: Medically important health conditions; recent use of prescription or non-prescription medications.
  • Subjects with renal disease: Subjects requiring dialysis; certain chronic medical conditions; patients who have received renal transplant; severe and/or poorly controlled diabetes; Treatment with protocol-specified drugs that may alter the way the body absorbs or processes CP-945,598.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00472836
Other Study ID Numbers  ICMJE A5351038
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP